# ATTR Expanded Access Program (EAP) by Ionis

> **NCT03400098** · — · APPROVED_FOR_MARKETING · sponsor: **Ionis Pharmaceuticals, Inc.**

## Conditions studied

- Amyloidosis, Hereditary

## Interventions

- **DRUG:** Inotersen

## Key facts

- **NCT ID:** NCT03400098
- **Lead sponsor:** Ionis Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** EXPANDED_ACCESS
- **Status:** APPROVED_FOR_MARKETING
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2019-08-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03400098

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03400098, "ATTR Expanded Access Program (EAP) by Ionis". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT03400098. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*